PharmaShots Weekly Snapshots (November 27

This week PharmaShots’ news was all about the updates on Pharma, Regulatory, Clinical Trials, DigiHealth, M&A & BioSimilar. Check out our full report below:

Dx&Vx and Oxford Vacmedix to Collectively Conduct Clinical Trials for OVM-200 as an Oncology Therapy

Read More: Dx&Vx & Oxford Vacmedix

RemeGen Highlights the P-II Trial Results for Disitamab Vedotin to Treat Urothelial Carcinoma

Read More: RemeGen

Anaptys Gains Exclusive License to Centessa Pharmaceuticals' BDCA2 Modulator Antibody Portfolio

Read More: Centessa Pharmaceuticals

Avidity Biosciences Expands Partnership with BMS for $2.3B to Advance Cardiovascular Treatments

Read More: Avidity Biosciences & BMS

Ascendis Signs Collaboration Agreement with Teijin Limited to Develop & Commercialize TransCon hGH, TransCon PTH, & TransCon CNP in Japan

Read More: Ascendis & Teijin Limited

Boehringer Ingelheim and Phenomic Signed Licensing Agreement to Develop Treatments for Tumors Rich in Stroma

Read More: Boehringer Ingelheim & Phenomic

SyntheticMR and Philips Jointly Introduce SyMRI 3D Revolutionizing Neuroimaging

Read More: SyntheticMR & Philips

The NMPA Grants Priority Review for Lung Cancer and Accepts GenFleet Therapeutics' NDA for GFH925

Read More: GenFleet Therapeutics

The US FDA Approved SpringWorks Therapeutic’s Ogsiveo for the Treatment of Desmoid Tumors

Read More: SpringWorks Therapeutics

Japan’s MHLW Approved CSL & Arcturus Therapeutics’ ARCT-154 for the Treatment of COVID

Read More: CSL & Arcturus Therapeutics

Transit Scientific Receives the US FDA Approval for Next-Generation Microcatheter

Read More: Transit Scientific

The US FDA-approved Alafair Bioscience’s VersaWrap to Manage and Protect Tendon Injuries as well as Peripheral Nerve Injuries

Read More: Alafair Bioscience

Astellas & Seagen Reports that the sBLA Padcev + Keytruda was Accepted by the US FDA for the 1L Treatment of Urothelial Cancer with a Priority Review

Read More: Astellas & Seagen

GSK Highlights the P-III Trial Results for Blenrep (belantamab mafodotin) to Treat Multiple Myeloma

Read More: GSK

Sanofi Highlights the P-III Trial Results for Dupixent to Treat Chronic Obstructive Pulmonary Disease (COPD)

Read More: Sanofi

EnGeneIC’s Publishes the Results of EnGeneIC Dream Vector (EDV) Nanocell Treatment for Pancreatic Cancer Patients in “Clinical Cancer Research”

Read More: EnGeneIC

Argenx Announces the Results of VYVGART Hytrulo in P-III Trial for Primary Immune Thrombocytopenia

Read More: Argenx

Akeso’s Cadonilimab Showed Positive Results in P-III Trial for Cervical Cancer Treatment

Read More: Akeso

Merck announces the Results of P-III trial (STRIDE-3) for V116 for the treatment of COVID-19 in adults

Read More: Merck

Sequane Medical Highlights the Results of P-I/IIa (MOJAVE) Study for DSR 2.0 in CHF Patients

Read More: Sequane Medical

Bio-Thera Announced BAT2206 (Ustekinumab) Positive Outcomes in P-III Study for Patients with Plaque Psoriasis

Read More: Bio-Thera

Abbvie's P-II (LUMINOSITY) Study of Telisotuzumab-Vedotin (Teliso-V) Reveals Positive Result for the Treatment of NSCLC

Read More: Abbvie

Opsidio Initiates Phase IIa (Opscf-201) Study for Atopic Dermatitis with the First Patient Dosing

Read More: Opsidio

Polaris Launches Phase IIa Clinical Study for NASH, Administers First Dose of ADI-PEG 20

Read More: Polaris

Calliditas Initiates P-II Clinical Trial for Setanaxib in Alport Syndrome

Read More: Calliditas

Innovent Highlights the Result Of P-II Study for IBI351 in The Treatment of Non-Small Cell Lung Cancer (NSCLC) and Colorectal Cancer (CRC)

Read More: Innovent

Revvity Launches EONIS Q System to Screen and Detect Newborns Suffering from Severe Combined Immunodeficiency (SCID) and Spinal Muscular Atrophy (SMA)

Read More: Revvity

MyBreastAI Suite introduced by GE HealthCare for Breast Cancer Detection

Read More: GE HealthCare